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Abstract
Background: Medical cannabis dispensaries following the social or hybrid model offer supplementary holistic
services in addition to dispensing medical cannabis. Historically, alternative physical health services have been the
norm for these dispensaries, including services such as yoga, acupuncture, or chiropractor visits. A clinical service
dearth remains for medical cannabis patients seeking substance use, misuse, dependence, and mental health
services. This study examined patient desires for various clinical services and level of willingness to participate in
specific clinical services.
Methods: Anonymous survey data (N = 303) were collected at Harborside Health Center (HHC), a medical
cannabis dispensary in Oakland, CA. The sample was 70% male, 48% Caucasian and 21% African American. The
mean male age was 38 years old and female mean age was 30. Sixty two percent of the male participants and
44% of the female participants are single. Sixteen percent of the population reported having a domestic partner.
Forty six percent of the participants are employed full time, 41% have completed at least some college, and 49%
make less than $40,000 a year.
Results: A significant portion of the sample, 62%, indicated a desire to participate in free clinical services at HHC,
34% would like more information about substances and use, and 41% want to learn more about reducing harms
from substance use. About one quarter of the participants marked “would” or “likely would” participate in
individual services such as consultation. Approximately 20% indicated “would” or “likely would” participate in
psycho-educational forums, harm reduction information sharing sessions, online support groups, and coping, life,
and social skills group. There was little interest in traditional NA/AA 12-step groups or adapted 12-step groups.
Conclusions: Desired clinical services can be qualified as a combination of harm reduction, educational, skills-
based, peer support and therapeutic individual and group services. Results suggest that medical cannabis patients
seek more information about various substances, including cannabis. Dispensaries can help to decrease gaps in
substance education and clinical services and fulfill unmet clinical desires. More research is necessary in additional
medical cannabis dispensaries in different geographic settings with different service delivery models.
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Background
Individuals who use medical cannabis for therapeutic
purposes are a diverse, evolving, and a generally under-
studied medical cohort. An increasing shift from the use
of “mainstream” medications, namely pharmaceuticals,
to the use of “natural” or alternative medications has
been observed [1,2]. The most noted reasons for the
transition from synthetic medication to medical
cannabis include: perception that conventional medica-
tion was problematic and/or ineffective, cannabis pro-
duced fewer side effects (or drawbacks), and cannabis
resulted in better symptom control and increased relief
when compared to previous treatments and medications
[2-4]. Cannabis is viewed as more “natural,” when com-
pared to manufactured synthetic medication, which is
appealing for some medication consumers [2].
In select states, such as California, Colorado and
Maine, there is an emergence of secure and reliable
access to cannabis through medical cannabis
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censed and illegal at the federal level and are still sub-
ject to federal enforcement efforts. Also known as
patient collectives, buyers’ clubs, or wellness centers,
these community based health facilities provide cannabis
to individuals who have obtained a doctor recommenda-
tion for its medical use. These facilities enable medical
cannabis patients to safely purchase medication and
many facilities offer a range of products from dried can-
nabis flowers and cannabis concentrates to various
forms of topical and edible cannabis products [5].
Medical cannabis health centers may provide an
opportune therapeutic setting to offer other clinical ser-
vices, such as substance misuse and related mental
health clinical services [6]. In a study by Reiman (2008),
sixty six percent of the patients surveyed reported utili-
zation of the holistic services in San Francisco Bay Area
medical cannabis facilities [5]. Currently, various social
and physical services are offered at dispensaries such as
massage therapy, nutritional and herbal consultations,
peer groups, and acupuncture are offered at some dis-
pensaries [5]. However, few dispensaries offer clinical
services related to substance use, misuse, dependence,
and mental health services.
The National Survey on Drug Use and Health demon-
strates the longstanding unmet clinical service need of
individuals seeking substance misuse, addiction, and
mental health services in the United States. The most
recent survey in 2009 shows that almost 9 percent of
the U.S. population, or 22.5 million people, were cate-
gorized to fit the substance abuse or dependence diag-
nosis, but 1.7 percent, or 4.3 million people, received
treatment for substance misuse [7]. The poor availability
of treatment services is referred to as a service gap for
the general population, meaning more individuals desire
services than there are services available.
Restrictive entrance parameters and program rules
such as a “clean” drug tests (meaning free from all sub-
stances), are often a condition for receiving services [8].
Other noted barriers include: the high cost of private
treatment services, lack of insurance, and not wanting to
be(or failing to be) abstinent, which is required in many
clinical settings [9]. Given the abstinence demands of
many treatment programs, having a medical cannabis
patient status may in itself be a barrier to receiving
desired services for mental health and substance misuse
and addiction. The need for integrated clinical services
at cannabis health centers can also driven by a lack of
formal substance health education, resulting in ill
informed substance consumers. In addition, because
cannabis is different than other traditional medications,
patients might have less traditional medical guidance,
and little empirical, applied data to refer to about safe
and effective medical cannabis use. Substance use stigma
also continues to be a barrier for individuals seeking
treatment for substance misuse. Clinical services inte-
grated within medical cannabis health centers may help
close service gaps and reduce service barriers for those
seeking services.
One promising area in the nexus of medical cannabis
and substance abuse treatment is the potential of can-
nabis to serve as a tool to assist a person to “exit” or
relinquish and abstain from another more harmful
substance [10]. Individuals who use cannabis to assist
in reducing or abstaining from the use of other sub-
stances, either viewed their substitution as very effec-
tive or effective in curbing the harms associated with
addiction [11]. Substance substitution studies show a
large percentage of individuals use medical cannabis as
a substitute for alcohol (40%), for illicit substances
(26%), and prescription drugs (65.8%) [5,12]. Substance
substitution with cannabis has been related to fewer
side effects and increased symptom management as
compared to other substances [5]. In a recent study of
medical cannabis patient profiles revealed that 51 per-
cent report using cannabis as a substitute for prescrip-
tion medication, supporting previous research on
cannabis substitution [13].
Cannabis may also serve as a useful therapeutic alter-
native for individuals seeking addiction and mental
health symptom management [14-16]. A meta-analysis
on the subjective effects of cannabis found that the
most frequently reported effects were: improved mood
(i.e., feeling good, happy, content), enhanced relaxation,
increased insight into self and others, and improved per-
ceptions. Of the reviewed close-ended studies, improved
thinking, increased concentration, and increased relaxa-
tion were frequently endorsed. Authors note individual
variations due to substance tolerance, setting, and cogni-
tive set [17]. Surveys from Australia and Germany and
exploratory studies in Canada and the United states find
that 12 to 56 percent of medical cannabis users report
u s ef o rr e l i e fo fs y m p t o m so f depression, 6 percent for
the relief of anxiety symptoms, and 6 percent for relief
from other psychological disorders [3,18-20].
Recent findings show that current medical cannabis
consumers might fare as well or better than other
cohorts who enter addiction treatment. Preliminary find-
ings indicate that medical cannabis use does not inter-
fere negatively with traditional substance addiction
treatment; in fact medical cannabis patients had a higher
treatment completion rate when compared to other
individuals in treatment [21]. Additionally, two studies
demonstrate that intermittent cannabis users show
superior retention in naltrexone opiate treatment
[22,23].
This exploratory study asks the question: What is the
level of desire for and willingness to participate in
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among medical cannabis patients? This study attempted
to capture the “patient voice” to inform the creation of
a harm reduction clinical services program at a hybrid
model dispensary in Oakland, CA.
Methods
Sample
Survey participants were patient members of Harbor-
side Health Center (HHC), a medical cannabis collec-
tive located in Oakland, CA. To date the HHC patient
membership is approximately 45,000 individuals. The
survey sample included 303 medical cannabis patients
between the ages of 18 and 75. The mean age was 38
years old. The sample was 70.3% male, 48.2% Cauca-
sian, and 20.8% African American. Fifty six percent
were single and 7.6% report to have a domestic part-
ner. Sixty two percent are employed, 15% are on dis-
ability income, and 37% have attained a bachelor or
graduate degree. Fifty one percent of the sample
earned over $40,000 annually.
Materials
Researchers created the survey and included direct sec-
tions from a Reiman 2009 survey of patients accessing
cannabis through Berkeley Patients Group (N = 350).
The survey contained a total of 48 questions including
1 4y e so rn oq u e s t i o n s ,1 8likert scale questions, 11
multiple choice questions, and 5 open-ended questions.
The domains of interest included: basic patient demo-
graphic information; present use of cannabis, alcohol,
tobacco, and other substances and use in past 30 days;
prior experiences with clinical services and possible bar-
riers encountered with services; patient desire to change
substance use related behaviors; desire for more infor-
mation about substances and substance use; and level of
willingness to participate in particular clinical services at
HHC.
Procedures
The lead researcher collected data at the dispensary dur-
ing the hours of 11 am to 8 pm over a 4-week time per-
iod, including weekdays and weekends. After the
mandatory patient check-in, front desk staff asked every
patient to participate in an anonymous survey. If the
individual was willing to participate, the researcher
briefly explained the purpose of the survey, confidential-
ity and risks of participation, and the right to refuse or
stop the survey. Informed consent information was also
provided in written form. Harborside Health Center
funded this survey as part of a program development
proposal. Data were analyzed and frequencies were
calculated.
Results
Medical cannabis, alcohol, tobacco, and other substance
use
Eighty eight percent of the sample reported daily use of
medical cannabis and 28% of the sample consume 3 to
5 grams of cannabis per week. Fifty five percent cur-
rently drink alcohol and the average number of drinking
days per month was 8.95. Twenty five percent report
tobacco use and 15% of the sample have used another
substance within the past 30 days. Of the individuals
who used another substance other than cannabis, alco-
hol, or tobacco (N = 46), pharmaceuticals account for
58.70% of the substances used. Furthermore, opiate-
derived pharmaceuticals account for 39.13% of the sub-
stances used (Table 1, 2).
Substance misuse and addiction treatment
Four percent of the sample had previously attended treat-
ment services for alcohol dependence, 2% currently attend
12-step support groups, and 10% have received treatment
for substance-related problems in the past. Five percent
had previously been diagnosed with a substance depen-
dence disorder. Eight percent had wanted to attend treat-
ment for substance misuse or dependence but did not
participate. Of those participants who wanted to attend
treatment but did not attend, the following reasons were
most noted: not ready for change (3%), couldn’ta f f o r di t
(2%), program philosophy (2%), required abstinence (2%),
drug testing policies (2%), and none available (2%).
Desire to change substance use behaviors
Seventy five percent of the current tobacco smokers
“probably” to “definitely” want to abate or stop the use
of tobacco. Seventy three percent of the alcohol consu-
mers “probably do not” and “definitely do not” want to
reduce or stop use of alcohol. Fifty eight percent of the
individuals who used another substance in the last 30
days “probably do not” and “definitely do not” want to
reduce or stop use of the specified substance (Table 3).
Desire for clinical services at a medical cannabis health
center
Thirty four percent reported wanting want access to
more factual information about substances and
Table 1 Medical Cannabis, Alcohol, and Tobacco Usage
Within Past 30 Days Reported by Medical Cannabis
Patients (N = 303)
Substance Reported Usage Percent of Survey Participants
Medical Cannabis 303 100.00%
Alcohol 166 54.79%
Tobacco 76 25.08%
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to reduce harms from substance use. Sixty two percent
said they would participate in free clinical services at
Harborside Health Center, if the services were offered.
Twenty seven percent of the survey participants indi-
cated, “I will or I likely would” participate in brief indivi-
dual counseling and twenty five percent for individual
consultation, assessment, and referral. Twenty percent
marked “I will or I likely would” participate in mental
health forums, 19% in substance education sessions, 19%
in skills groups, and 17% in an online therapeutic sup-
port group. Less than 10% of the participants would or
likely would participate in recovery maintenance groups,
NA/AA 12-steps groups, and modified NA/AA 12-step
groups (Table 4).
Discussion
To date there are no studies asking medical cannabis
patients, who purchase medicine from a medical canna-
bis dispensary, about desires for dispensary based clini-
cal services. Prior to the introduction of potential
clinical services, at HHC a supplementary holistic care
center arose from patient demand. The clinical services
were described as an additional component to the holis-
tic care program. When patients were asked about harm
reduction services a marked desire for integrated clinical
services was reported. A large portion of the patients
sought more information about cannabis as well as
more information about other substances. This may
speak to the poor success rate of formal drug education
programs provided in schools and oversaturation of
information on the internet.
There was variance in type of clinical service desired.
Two hundred and twenty five of the survey participants
“would” or “most likely would” seek individual services
including individual counseling, individual assessment and
referral, and individual consultation with a psychiatrist for
medication supports. One hundred and seventy three of
the participants indicated desire for life skills groups such
as problem solving and decision making, anger manage-
ment skills, stress management, coping skills, and relational
and communication skills. The high saturation of group
services available in the community may be one explana-
tion as to why group services, particularly AA/NA or 12-
step groups, were not desired by the survey participants. A
negative reputation, zero-tolerance for cannabis, and a lack
of need may be reasoning for the participants’ low level of
desire to participate in this type of clinical service.
Results indicate that the majority of the medical can-
nabis patients do not use, misuse, or become addicted
to illegal substances. This is evident in the use data, as
well as the current and past treatment data. A small
cohort of the medical cannabis patients currently
(3.63%) or have in the past (14.52%) attended a treat-
ment program for substance misuse or addiction, how-
ever the majority of patients have not recently used an
illegal substance (85%), have never sought treatment,
and did not find treatment necessary for any substance
including cannabis. Medical cannabis patients who use
tobacco were the only group of individuals dissatisfied
with their behavior, indicating a desire to reduce or quit
the use of this substance. The gateway theory theorizes
that an individual’s use of cannabis will lead the indivi-
dual into use, misuse, and addiction of other “hard” sub-
stances such as cocaine and heroin. Many studies refute
this theory including this exploratory study [24-27].
Table 2 Other Substance Usage Within Past 30 Days Reported by Medical Cannabis Patients (N = 303)
Substance Reported Usage Percent of Survey Participants
Opioid Pharmaceuticals 18 5.95%
Hallucinogens 11 3.63%
MDMA/Ecstasy 10 3.30%
Cocaine/Crack Cocaine 7 2.31%
Benzodiazepine Pharmaceuticals 6 1.98%
Other Substances 5 1.65%
Stimulant Pharmaceuticals 3 0.99%
Methamphetamine 2 0.66%
Heroin 0 0.00%
Opioid pharmaceuticals may include Vicodin, Percocet, Codeine, Hydrocodone, Oxycodone, Buprenorphine, Fentanyl, etc. Hallucinogens may include psilocybin
mushrooms, mescaline, LSD, etc. Benzodiazepine pharmaceuticals may include Valium, Ativan, Xanax, Klonopin, Rohypnol, etc. Stimulant pharmaceuticals may
include Concerta, Adderall, Dexedrine, Ritalin, etc.
Table 3 Desire to Reduce or Stop the Use of Tobacco,
Alcohol and Other Drugs Reported by Medical Cannabis
Patients (N = 303)
Substance Definitely
Not
Probably
Not
Maybe Probably Definitely
Tobacco 2 6 12 16 41
Alcohol 66 46 24 9 10
Other
Substances
46 20 9 5 7
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universal data system at medical cannabis health centers
that catalogue patient characteristics, therefore represen-
tation of HHC patient membership (N = ~45,000 indivi-
duals) is unclear. Recent descriptive studies of medical
cannabis patients reveal that survey participant charac-
teristics in this study such as age, gender, and employ-
ment status resemble those in the California medical
cannabis patient cohort [4,5,13]. In addition, the sur-
veyed patient population by and large mimics the gen-
eral population characteristics of the surrounding area.
Similar to the sample characteristics, the median age is
39 in the San-Francisco-Oakland-Fremont metropolitan
statistical area [28]. When compared to census data a
slight overrepresentation of males and single individuals
in the sample may have occurred. There may be sample
characteristic restrictions because the survey was admi-
nistered at one medical cannabis dispensary over a lim-
ited time period. Since little is known about the
frequency of patient visits, a 4-week data collection win-
dow may have missed a subsection of patients. Extre-
mely ill patients may have been unable to participate
because of mobility limitations or inability to frequent
the health center. Additionally, this survey does not
account for the individuals who use cannabis medicin-
ally without a physician recommendation and therefore
are not patronizing medical cannabis dispensaries for
medication. Last, self-selection may be present as related
to the past illegal status of cannabis and societal stigma
of substance use.
While survey data was used for applied purposes, find-
ings show that medical cannabis patients desire clinical
services, qualified as a combination of harm reduction,
educational, skills-based, peer support and therapeutic
individual and group services. Medical cannabis dispen-
saries can help to decrease commonplace clinical service
gaps and fulfill unmet clinical desires. More research is
necessary in additional medical cannabis dispensaries in
other jurisdictions and with potentially different service
delivery models to help uncover the characteristics of
this once abjured cohort.
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